Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Clinical News

CRLX101: Phase I/II started

May 16, 2016 7:00 AM UTC

Cerulean said NIH’s NCI began an open-label, U.S. Phase I/II trial to evaluate IV CRLX101 in combination with oral Lynparza olaparib from AstraZeneca plc (LSE:AZN; NYSE:AZN, London, U.K.). The Phase I portion will enroll up to 30 patients to identify the MTD or recommended Phase II dose. NCI is conducting the trial in collaboration with Cerulean and AZ. ...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article